These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38288923)

  • 21. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
    Furie R; Morand EF; Bruce IN; Isenberg D; van Vollenhoven R; Abreu G; Pineda L; Tummala R
    Arthritis Rheumatol; 2021 Nov; 73(11):2059-2068. PubMed ID: 33913260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis.
    Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Kawakami A; Hayashi N; Abreu G; Yavuz S; Lindholm C; Al-Mossawi H; Takeuchi T
    Mod Rheumatol; 2024 Jul; 34(4):720-731. PubMed ID: 37706527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
    Clowse ME; Wallace DJ; Furie RA; Petri MA; Pike MC; Leszczyński P; Neuwelt CM; Hobbs K; Keiserman M; Duca L; Kalunian KC; Galateanu C; Bongardt S; Stach C; Beaudot C; Kilgallen B; Gordon C;
    Arthritis Rheumatol; 2017 Feb; 69(2):362-375. PubMed ID: 27598855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.
    Yee CS; Gordon C; Isenberg DA; Griffiths B; Teh LS; Bruce IN; Ahmad Y; Rahman A; Prabu A; Akil M; McHugh N; Edwards CJ; D'Cruz D; Khamashta MA; Farewell VT
    Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1623-1630. PubMed ID: 33787088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB
    Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
    Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C
    Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
    Chia YL; Tummala R; Mai TH; Rouse T; Streicher K; White WI; Morand EF; Furie RA
    J Clin Pharmacol; 2022 Sep; 62(9):1094-1105. PubMed ID: 35352835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 33. Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients.
    Flouda S; Emmanouilidou E; Karamanakos A; Koumaki D; Katsifis-Nezis D; Repa A; Bertsias G; Boumpas D; Fanouriakis A
    Lupus; 2024 Oct; 33(11):1248-1253. PubMed ID: 39098049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures.
    Thanou A; James JA; Arriens C; Aberle T; Chakravarty E; Rawdon J; Stavrakis S; Merrill JT; Askanase A
    Lupus Sci Med; 2019; 6(1):e000365. PubMed ID: 31921432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.
    Furie R; Wang L; Illei G; Drappa J
    Lupus; 2018 May; 27(6):955-962. PubMed ID: 29460699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
    Yee CS; Farewell V; Isenberg DA; Rahman A; Teh LS; Griffiths B; Bruce IN; Ahmad Y; Prabu A; Akil M; McHugh N; D'Cruz D; Khamashta MA; Maddison P; Gordon C
    Arthritis Rheum; 2007 Dec; 56(12):4113-9. PubMed ID: 18050213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Lipsky P; Fei K; Gordon RM; Gregan I; Lo KH; Chevrier M; Rose S
    Arthritis Rheumatol; 2020 May; 72(5):761-768. PubMed ID: 31769212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.
    Tummala R; Abreu G; Pineda L; Michaels MA; Kalyani RN; Furie RA; Morand EF
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33597205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.
    Urowitz MB; Isenberg DA; Wallace DJ
    Lupus Sci Med; 2015; 2(1):e000104. PubMed ID: 26301100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.